After decades in Big Pharma, Kelly Page heads to 'growth stage'; Allied with Novartis, Bicycle selects development chief
Following a decades-long career in Big Pharma, Kelly Page wanted to use her research and commercial experience to help a small company grow.
Last Tuesday, she started at Arvinas, a Pfizer-partnered biotech looking to harness the body’s protein disposal system to degrade disease-causing proteins. She has taken the role of senior VP and global head of oncology strategy and program leadership, a field that’s motivated her personally since three close relatives were diagnosed with lymphoma in 1999.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.